A leading international partner of the biopharmaceutical industry and the research sector, Sartorius increased its sales revenue in the first quarter of 2018 by 11.4% (reported: 6.3%), with acquisitions contributing around 4% to this growth. Order intake for the same period rose 12.4%.
CEO Dr. Joachim Kreuzburg said: "Both divisions started off the year strongly in line with our expectations and further increased their revenues in the first quarter of 2018 in all regions. On the currency side, however, we faced some headwinds, especially due to the weakness of the U.S. dollar against the euro, which dampened our profit growth. Order intake developed at an encouragingly strong level for both divisions so we look optimistically to the months ahead and confirm our full-year forecast".
“Sartorius looks back on a successful start to 2018. “
The Bioprocess Solutions Division, which offers a selection of innovative technologies for the manufacture of biopharmaceuticals, recorded first quarter sales growth of 10%, and management expect sales to grow 8%-11%, including non-organic growth of around .5% contributed to sales. Orders rose by 9.1%.
The Lab Products & Services Division, which sells products and technologies mainly for pharma labs and life science research, reported a 15.3% increase in revenue. Non-organic growth of approximately 11% was helped by the acquisition of Essen BioScience. Orders rose by 22.7%.